Drug
Olmesartan Medoxomil Hydrochlorothiazide
Olmesartan Medoxomil Hydrochlorothiazide: highest development phase Post-Market, developed by Daiichi Sankyo. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary NCT00890591 | Post-Market | Essential Hypertension |
| olmesartan medoxomil + hydrochlorothiazide, if necessary NCT00751751 | Phase 3 | Essential Hypertension |
Latest
No recent events.
Follow Olmesartan Medoxomil Hydrochlorothiazide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.